ChemoCentryx reported 5.25M in Gross Profit on Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Abbvie ABBV:US $ 9517M 1089M
Alnylam Pharmaceuticals ALNY:US $ 177.63M 43.24M
Amgen AMGN:US $ 4677M 451M
AstraZeneca AZN:LN 9.11B 169M
Bayer BAYN:GR 9.46B 2.03B
Biogen BIIB:US $ 1777.9M 295.8M
Biomarin Pharmaceutical BMRN:US $ 402.39M 72.33M
Bristol Myers Squibb BMY:US $ 9177M 452M
ChemoCentryx CCXI:US 5.25M 3.24M
GlaxoSmithKline GSK:LN 6.14B 283M
Glaxosmithkline GSK:US $ 6135M 283M
Johnson & Johnson JNJ:US $ 15828M 1021M
MacroGenics MGNX:US 11.05M 2.15M
Merk MRK:US $ 10567M 873M
Novartis NOVN:VX 9.06B 463M
Pfizer PFE:US $ 15651M 1627M
Sarepta Therapeutics SRPT:US $ 179.39M 9.67M
Takeda 4502:JP Y 564909M 54981M
Teva Pharmaceutical TEVA:IT 1.8B 323M
YTE INCY:US $ 696.02M 128.26M